Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

Discover 10 causes of nasal breathing difficulties from deviated septum to spray addiction, plus effective solutions for ...

As flowers bloom and temperatures climb, spring brings in allergy season for many. When sneezing, itchy eyes or sinus ...

could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been shown to reduce symptoms. Sanofi ...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

Blood basophils among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) may indicate the degree of inflammation, according to findings published in the European Archives of ...

An NHS doctor has warned specific people against using nasal sprays, warning that doing so could induce "horrible" symptoms. Nasal decongestants are widely sought after for those needing respite ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Certain people have been warned against using nasal sprays by an NHS doctor. According to the expert, doing so could result in some “horrible” symptoms. Nasal decongestants can be a much ...